Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Change in Accured Expenses (2016 - 2025)

Lineage Cell Therapeutics' Change in Accured Expenses history spans 16 years, with the latest figure at $2.5 million for Q4 2025.

  • For Q4 2025, Change in Accured Expenses rose 2435.05% year-over-year to $2.5 million; the TTM value through Dec 2025 reached $2.3 million, up 235.1%, while the annual FY2025 figure was $2.3 million, 235.1% up from the prior year.
  • Change in Accured Expenses reached $2.5 million in Q4 2025 per LCTX's latest filing, up from $271000.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $21.3 million in Q4 2021 to a low of -$18.9 million in Q1 2022.
  • Average Change in Accured Expenses over 5 years is $61900.0, with a median of -$215000.0 recorded in 2022.
  • Peak YoY movement for Change in Accured Expenses: plummeted 1733.66% in 2022, then skyrocketed 2435.05% in 2025.
  • A 5-year view of Change in Accured Expenses shows it stood at $21.3 million in 2021, then plummeted by 105.3% to -$1.1 million in 2022, then skyrocketed by 202.83% to $1.2 million in 2023, then crashed by 91.65% to $97000.0 in 2024, then surged by 2435.05% to $2.5 million in 2025.
  • Per Business Quant, the three most recent readings for LCTX's Change in Accured Expenses are $2.5 million (Q4 2025), $271000.0 (Q3 2025), and -$354000.0 (Q2 2025).